A Study to Evaluate the Tolerability of Botox and Topiramate or Botox and Placebo and Effect on Cognitive Efficiency
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate sustained tolerability, quality of life, and change
in cognitive efficiency following treatment with OnabotulinumtoxinA and daily topiramate vs.
OnabotulinumtoxinA and daily placebo (Group A vs. Group B).
Phase:
Phase 4
Details
Lead Sponsor:
Cady, Roger, M.D.
Collaborator:
Allergan
Treatments:
abobotulinumtoxinA Botulinum Toxins Botulinum Toxins, Type A incobotulinumtoxinA onabotulinumtoxinA Topiramate